Adagene Inc.

NASDAQ:ADAG

Biotechnology

Healthcare
$1.82 +3.68%

+$0.13 today

Market cap
$68.52M
Beta
0.59
P/E (TTM)
-7.9
EPS (TTM)
-$0.47
52W Low $1.30High $4.75

Volume 1.30M

Average 0.21M

ADAG Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Adagene Inc.NASDAQ: ADAG

Net Income · Q4 FY2025 · quarter ended Dec 2025

Net income declines year over year

Q4 FY2025 net income of $4.14M (cash outflow) fell 83.4% year over year, behind the -12.6% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -39.6% a year.

Context

  • Net income amounted to 229.6% of revenue in FY2025, down 32156.9 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of -$21.98M (+24.8%) for the fiscal year ending Dec 2026, a step up from the -47.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-$4.14M— QoQ
Last fiscal yearDec 2025
-$17.61M-47.3% YoY
LTMJun 2024
-$31.85M-12.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-83.4%——
1 year-47.3%+24.8%+72.1 pp
3-year CAGR-39.6%+11.0%+50.6 pp
5-year CAGR+11.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(17.61M) USD
Year-over-year change
+47.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ADAG compares with its peers on the latest reported figures

  • ADAG's LTM Jun 2024 net income of $31.85M is the 6th largest of the 9 companies compared; the peer median is $32.35M.
  • Net income amounts to 3904.3% of revenue for ADAG, versus a peer median of 759.3%.
ADAG Competitors Peer median
Net Income for ADAG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OSTXOS Therapies IncorporatedLTM Mar 2026$28.76B +254398.4%+1562.8%—
TCRXTScan Therapeutics, Inc.LTM Mar 2026$124.31M -5.5%+25.1%1360.6%
ACETAdicet Bio, Inc.LTM Mar 2026$108.83M -7.2%+18.7%—
FBIOFortress Biotech, Inc.LTM Mar 2026$102.15M +215.2%-46.4%154.4%
XBITXBiotech Inc.LTM Mar 2026$40.16M +1.9%+11.4%—
ADAGAdagene Inc.LTM Jun 2024$31.85M —-39.6%3904.3%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$24.54M +1.8%-10.4%1070.2%
GANXGain Therapeutics, Inc.LTM Mar 2026$21.24M +1.5%+4.7%—
NTRBNutriband Inc.LTM Apr 2026$8.08M -19.0%+22.4%448.4%
Peer median (excluding ADAG) $32.35M+1.6%+15.1%759.3%

Competitors are the stored peer set for ADAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73.18M)(79.97M)(18.95M)(33.42M)(17.61M)
Depreciation & Amortization1.13M1.45M1.21M926.25K589.79K
Deferred Income Tax622.43K(44.16K)000
Stock-Based Compensation18.68M10.52M7.27M4.91M3.74M
Change in Working Capital9.35M21.94M(16.55M)(1.89M)(775.3K)
Accounts Receivables(3M)6.89M397.41K213.72K(9.04K)
Inventory6.02M0000
Accounts Payables1.51M344.51K(572.37K)1.15M(1.36M)
Other Working Capital4.82M14.75M(16.38M)(3.25M)591.01K
Other Non-Cash Items(9.95K)(2.5M)(1.44M)(222.24K)(1.6M)
Operating Cash Flow(43.41M)(48.61M)(28.45M)(29.7M)(15.66M)
Capital Expenditures(2.51M)(690.94K)(85.01K)(33.58K)(17.05K)
Acquisitions (Net)00000
Purchases of Investments00(47M)(128.5M)(80M)
Sales of Investments0047M129.64M80.49M
Other Investing Activities04.89K7.66K1691.4K
Investing Cash Flow(2.51M)(686.05K)(77.36K)1.11M476.8K
Debt Repayment(702.86K)21.48M(5.37M)(3.42M)(12.24M)
Common Stock Issued149.79M05.5K7.33M138.28K
Common Stock Repurchased(2.36M)(3.98M)000
Dividends Paid00000
Other Financing Activities(1.37M)323.21K5.5K(137.3K)0
Financing Cash Flow145.36M17.82M(5.37M)3.77M4.45M
Effect of Forex Changes(192.35K)842.2K74.72K81.88K64.55K
Net Change in Cash99.24M(30.63M)(33.82M)(24.74M)(10.67M)
Free Cash Flow(45.92M)(49.3M)(28.54M)(29.73M)(15.67M)

Adagene Inc.

NASDAQ:ADAG

Intrinsic Alpha fair value

Locked

Current Price

$1.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.